Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09BDE
|
||||
| Former ID |
DIB008077
|
||||
| Drug Name |
PAC-14028
|
||||
| Indication | Atopic dermatitis [ICD9: 691.8, 692.9; ICD10:L00-L99] | Phase 2 | [1] | ||
| Company |
Pacific Pharmaceuticals Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Vanilloid receptor 1 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | |||||
| Reactome | TRP channels | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02052531) Efficacy and Safety Study of PAC-14028 Cream in Dermal Pruritus. U.S. National Institutes of Health. | ||||
| REF 2 | Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.